



pharma& joins the United Nations Global Compact

This news release is intended for the media

Vienna, Austria, April 30, 2024 – pharmaand GmbH (pharma&) announced today it has joined the United Nations Global Compact initiative, a voluntary leadership platform for the development, implementation, and disclosure of responsible business practices. The UN Global Compact is a call to companies everywhere to align their operations and strategies with ten universally accepted principles in the areas of human rights, labor, environment, and anti-corruption and to act in support of UN goals and issues embodied in the Sustainable Development Goals (SDGs).

"Today marks an important moment as pharma&, a Company that is breathing new life into proven medicines, proudly announces its inclusion in the United Nations Global Compact. With this significant step, we, along with the more than 20,000 business participants, affirm our commitment to upholding the principles of sustainable development, human rights, labor standards, and environmental stewardship," said Frank Rotmann, Founder and Managing Director, pharma&. "As we embark on this journey, we recognize pharma&'s responsibility and the opportunity to contribute positively to the global community. We strive for our organization to make a difference to ensure a more equitable, inclusive, and sustainable future for all."

Launched in 2000, the UN Global Compact is the largest corporate sustainability initiative in the world, with more than 9,500 companies and 3,000 non-business signatories based in over 160 countries and more than 70 local networks. [Click here](#) to learn more about the UN Global Compact initiative.

About pharma&

[pharmaand GmbH \(pharma&\)](#), a privately owned global company, aspires to breathe new life into proven medicines through an agile and fully integrated business model, and aims to guarantee the enduring availability, dependability, and quality of essential drugs worldwide that patients and healthcare providers rely on. Over the past five years, pharma& has acquired and integrated 10+ medicines, expanding its portfolio

across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. The Company's unique synthesis of subsidiaries, joint ventures, and partners enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of development, product and API manufacturing, partner distribution, healthcare provider engagement, distribution, and services to patients.

#

pharma& Media Contact:

media@pharmaand.com